Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aimmune Therapeutics, Inc.    AIMT

AIMMUNE THERAPEUTICS, INC.

(AIMT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2018 - - -
Net income 2018 -211 M - -
Net cash position 2018 304 M - -
P/E ratio 2018 -6,52x
Yield 2018 -
Sales 2019 - - -
Net income 2019 -248 M - -
Net cash position 2019 89,6 M - -
P/E ratio 2019 -8,43x
Yield 2019 -
Capitalization 2 268 M 2 268 M -
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees 339
Free-Float 77,8%
More Financials
Company
Aimmune Therapeutics, Inc. is a biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens. PALFORZIA is its internally developed product utilizing CODIT.... 
More about the company
Notations Surperformance© of Aimmune Therapeutics, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about AIMMUNE THERAPEUTICS, INC.
10/21Nestle shrugs off COVID-19 impact thanks to pet food and health nutrition
RE
10/19AIMMUNE THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Com..
AQ
10/19AIMMUNE THERAPEUTICS : Receives Positive CHMP Opinion on PALFORZIA for the Treat..
AQ
10/15MONTEVERDE & ASSOCIATES PC : Files Class Action Lawsuit On Behalf Of Shareholder..
PR
10/15AIMMUNE THERAPEUTICS : Nestle Completes Acquisition of Aimmune Therapeutics
AQ
10/13AIMMUNE THERAPEUTICS : Nestle announces results of tender offer for Aimmune Ther..
AQ
10/13GLOBAL MARKETS LIVE: U.S. banks beat expectations
10/13Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With S..
DJ
10/13AIMMUNE THERAPEUTICS : shareholders accept $2 billion Nestle tender offer
RE
09/18Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics..
PR
09/15AIMMUNE THERAPEUTICS : Nestle commences tender offer for Aimmune Therapeutics In..
AQ
09/14AIMMUNE THERAPEUTICS : Nestlé commences tender offer for Aimmune Therapeutics, I..
PR
09/05KASKELA LAW LLC : Announces Stockholder Investigation of Aimmune Therapeutics, I..
PR
09/04AIMMUNE INVESTOR ALERT BY THE FORMER : Kahn Swick & Foti, LLC Investigates Adequ..
BU
09/01AIMMUNE THERAPEUTICS : Nestle to acquire Aimmune Therapeutics
AQ
More news
News in other languages on AIMMUNE THERAPEUTICS, INC.
10/21Wachstum von Nestle zieht an - Vitamine und Mineralien gefragt
10/21Nestlé wächst zweistellig mit Vitaminen und medizinischen Produkten
10/21NESTLÉ : des ventes solides aux 9 premiers mois de l'année
10/20AUSBLICK NESTLÉ : Organisches Wachstum im Q3 bei 2,6 Prozent erwartet
10/20PRÉVISIONS NESTLÉ : croissance organique de 2,6% au 3e trimestre
More news
Chart AIMMUNE THERAPEUTICS, INC.
Duration : Period :
Aimmune Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 34,49 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Jayson Donald Alexander Dallas President, Chief Executive Officer & Director
Mark D. McDade Chairman
Eric Hands Claude Bjerkholt Chief Financial Officer
Daniel C. Adelman Chief Medical Officer
Narinder Singh Executive Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
AIMMUNE THERAPEUTICS, INC.3.05%2 268
GILEAD SCIENCES, INC.-8.43%74 585
VERTEX PHARMACEUTICALS-0.39%56 714
REGENERON PHARMACEUTICALS35.38%53 649
WUXI APPTEC CO., LTD.56.53%37 691
BIONTECH SE209.80%25 273